Cipla stock jumps to all-time high; Nuvama raises target price, sees 18% upside

Cipla is aiming to transition from a pure-play pharma company to an integrated health player, per analysts.

Related Keywords

China ,United States ,Cipla Pharma ,Life Sciences ,Drug Administration ,Cipla ,Institutional Equities ,United States Food ,Jiangsu Province ,Generics Business Undertaking ,Life Sciences Limited ,Cipla Stock ,Cipla Shares ,Cipla Stock Price ,